CompletedPhase 4

Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis

United States16 participantsStarted 2014-09

Plain-language summary

The purpose of this study is to determine if abatacept (Orencia) is effective in patients with primary biliary cirrhosis who do not respond adequately to standard treatment with ursodeoxycholic acid (UDCA, Urso, Ursodiol, Actigall).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Anti-mitochondrial antibody (AMA) titer \> 1:40
✓. Alkaline phosphatase \> 1.5 times the upper limit of normal for at least 6 months
✓. Liver biopsy findings consistent with PBC

What they're measuring

Biochemical Response

Timeframe: Week 24

Trial details

NCT IDNCT02078882

SponsorChristopher Bowlus, MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-10

Results submitted2020-01-27

View on ClinicalTrials.gov More Primary Biliary Cirrhosis trials